Purpose

This is a Phase II, multicenter, non-randomized, open-label, multi-arm study designed to evaluate the safety and efficacy of targeted therapies as single agents or in rational, specified combinations in participants with advanced unresectable or metastatic solid tumors determined to harbor specific biomarkers. Patients will be enrolled based on local testing performed at a Clinical Laboratory Improvement Amendments (CLIA)-certified or equivalently accredited diagnostic laboratory. The multi-arm structure of the MyTACTIC study allows patients with solid tumors to be treated with a drug or drug regimen tailored to their biomarker identified at screening.

Condition

Eligibility

Eligible Ages
Over 18 Years
Eligible Genders
All
Accepts Healthy Volunteers
No

Inclusion Criteria

  • Histologically or cytologically confirmed diagnosis of advanced unresectable or metastatic solid malignancy - Positive biomarker results from a Clinical Laboratory Improvement Amendments (CLIA)-certified or equivalently accredited diagnostic laboratory and availability of a full report of the testing results. This may be from a tissue or blood sample. - Evaluable or measurable disease - Eastern Cooperative Oncology Group (ECOG) Performance Status 0-2 - Life expectancy ≥8 weeks - Adequate hematologic and end-organ function, as defined in the protocol, obtained within 14 days prior to initiation of study treatment - Agrees to take measures to prevent pregnancy in the patient or partner - In addition to the general inclusion criteria above, there are treatment-specific inclusion criteria that apply for each respective treatment arm (as detailed in the protocol)

Exclusion Criteria

  • Current participation or enrollment in another therapeutic clinical trial - Symptomatic or actively progressing CNS metastases (asymptomatic patients with treated or untreated CNS metastases may be eligible, provided all protocol-defined criteria are met) - History of leptomeningeal disease, unless noted otherwise for a specific treatment arm of the study - Wide field radiotherapy within 14 days prior to start of study treatment - Stereotactic radiosurgery within 7 days prior to start of study treatment - Severe infection within 4 weeks prior to initiation of study treatment, including, but not limited to, hospitalization for complications of infections, or any active infection that, in the opinion of the investigator, could impact patient safety - Receipt of any anticancer drug/biologic or investigational treatment 21 days prior to Cycle 1, Day 1 except hormone therapy, which can be given up to 7 days prior to Cycle 1, Day 1 (androgen blockage may be continued for male patients with prostate cancer) - Known HIV, hepatitis C virus (HCV), or hepatitis B virus (HBV) infection with status outside of study-allowed criteria - History of or concurrent serious medical condition or abnormality in clinical laboratory tests that precludes the patient's safe participation in and completion of the study or confounds the ability to interpret data from the study - History of malignancy other than disease under study within 3 years prior to screening, with the exception of malignancies with a negligible risk of metastasis or death - Incomplete recovery from any surgery prior to the start of study treatment that would interfere with the determination of safety or efficacy of study treatment - Major surgical procedure, other than for diagnosis, or significant traumatic injury within 4 weeks prior to initiation of study treatment, or anticipation of need for a major surgical procedure during the study - Significant cardiovascular disease, such as New York Heart Association cardiac disease (Class II or higher), myocardial infarction, or cerebrovascular accident within 3 months prior to enrollment, unstable arrhythmias, or unstable angina - Pregnant or breastfeeding, or intending to become pregnant during the study - In addition to the general exclusion criteria above, there are treatment-specific exclusion criteria that apply for each respective treatment arm (as detailed in the protocol)

Study Design

Phase
Phase 2
Study Type
Interventional
Allocation
Non-Randomized
Intervention Model
Parallel Assignment
Primary Purpose
Treatment
Masking
None (Open Label)

Arm Groups

ArmDescriptionAssigned Intervention
Experimental
Arm A: Entrectinib
Participants in this treatment arm must have a positive tumor biomarker result for ROS1 gene fusion.
  • Drug: Entrectinib
    Entrectinib will be self-administered by participants orally at home (except on clinic days), at the same time each day, on a starting dose of 600 milligrams (mg) per day once a day (QD) until disease progression, intolerable toxicity, or consent withdrawal.
    Other names:
    • Rozlytrek™
    • RG6268
    • RO7102122
Experimental
Arm B: Inavolisib
Participants in this treatment arm must have a positive tumor biomarker result for PI3KCA activating mutation.
  • Drug: Inavolisib
    Inavolisib will be self-administered by participants orally at home (except on clinic days) at the same time each day, on a starting dose of 9 mg/day QD until disease progression, intolerable toxicity, or consent withdrawal.
    Other names:
    • GDC-0077
    • RG6114
    • RO7113755
Experimental
Arm C: Alectinib
Participants in this treatment arm must have a positive tumor biomarker result for ALK rearrangement tumors.
  • Drug: Alectinib
    Alectinib will be self-administered by participants orally at home (except on clinic days), at the same times each day, on a starting dose of 600 mg twice a day (BID) until disease progression, intolerable toxicity, or consent withdrawal.
    Other names:
    • Alecensa®
    • RG7853
    • RO5424802
Experimental
Arm D: Ipatasertib
Participants in this treatment arm must have a positive tumor biomarker result for either AKT1/2/3 activating mutation or PTEN loss/loss of function.
  • Drug: Ipatasertib
    Ipatasertib will be self-administered by participants orally at home (except on clinic days), at the same time each day, on a starting dose of 400 mg QD until disease progression, intolerable toxicity, or consent withdrawal.
    Other names:
    • GDC-0068
    • RG7440
    • RO5532961
Experimental
Arm E: Atezolizumab + Investigator's Choice of Chemotherapy
Participants in this treatment arm must have a positive tumor biomarker result for either tumor mutational burden (TMB) high or microsatellite instability (MSI) high/deficient mismatch repair (dMMR).
  • Drug: Atezolizumab
    Atezolizumab will be administered by intravenous (IV) infusion at a fixed dose of 1200 mg for participants on Day 1 of each 21-day cycle until unacceptable toxicity or progressive disease (or loss of clinical benefit).
    Other names:
    • Tecentriq®
    • RG7446
    • RO5541267
  • Drug: Investigator's Choice of Chemotherapy
    Chemotherapy will consist of docetaxel, paclitaxel, or capecitabine, as determined by the investigator, and will be administered per the respective package insert and institutional guidelines.
Experimental
Arm F: Trastuzumab Emtansine + Atezolizumab
Participants in this treatment arm must have a positive tumor biomarker result for ERBB2 mutations or amplification without known TMB high or MSI high/dMMR.
  • Drug: Atezolizumab
    Atezolizumab will be administered by intravenous (IV) infusion at a fixed dose of 1200 mg for participants on Day 1 of each 21-day cycle until unacceptable toxicity or progressive disease (or loss of clinical benefit).
    Other names:
    • Tecentriq®
    • RG7446
    • RO5541267
  • Drug: Trastuzumab Emtansine
    Trastuzumab emtansine will be administered at 3.6 mg per kilogram (kg) of body weight by IV infusion every 21 days (unless dose reduction and/or dose delays are required) until disease progression or unacceptable toxicity.
    Other names:
    • Kadcyla®
    • RG3502
    • RO5304020
Experimental
Arm G: PH FDC SC
Participants in this treatment arm must have a positive tumor biomarker result for ERBB2 mutation or amplification without known TMB high or MSI high/dMMR.
  • Drug: Pertuzumab, Trastuzumab, and Hyaluronidase-zzxf
    PH FDC SC will be administered subcutaneously (SC) at a fixed non-weight-based dose. A loading dose of 1200 mg SC pertuzumab and 600 mg SC trastuzumab is then followed by a maintenance dose of 600 mg SC pertuzumab and 600 mg SC trastuzumab once every 3 weeks.
    Other names:
    • PHESGO™
    • PH FDC SC
    • Fixed dose combination of trastuzumab and pertuzumab administered subcutaneously
    • RG6264
    • RO7198574
Experimental
Arm H: PH FDC SC + Investigator's Choice of Chemotherapy
Participants in this treatment arm must have a positive tumor biomarker result for ERBB2 mutation or amplification without known TMB high or MSI high/dMMR.
  • Drug: Pertuzumab, Trastuzumab, and Hyaluronidase-zzxf
    PH FDC SC will be administered subcutaneously (SC) at a fixed non-weight-based dose. A loading dose of 1200 mg SC pertuzumab and 600 mg SC trastuzumab is then followed by a maintenance dose of 600 mg SC pertuzumab and 600 mg SC trastuzumab once every 3 weeks.
    Other names:
    • PHESGO™
    • PH FDC SC
    • Fixed dose combination of trastuzumab and pertuzumab administered subcutaneously
    • RG6264
    • RO7198574
  • Drug: Investigator's Choice of Chemotherapy
    Chemotherapy will consist of docetaxel, paclitaxel, or capecitabine, as determined by the investigator, and will be administered per the respective package insert and institutional guidelines.
Experimental
Arm I: Trastuzumab Emtansine + Tucatinib
Participants in this treatment arm must have a positive tumor biomarker result for ERBB2 mutation or amplification without known TMB high or MSI high/dMMR.
  • Drug: Trastuzumab Emtansine
    Trastuzumab emtansine will be administered at 3.6 mg per kilogram (kg) of body weight by IV infusion every 21 days (unless dose reduction and/or dose delays are required) until disease progression or unacceptable toxicity.
    Other names:
    • Kadcyla®
    • RG3502
    • RO5304020
  • Drug: Tucatinib
    Tucatinib 300 mg will be administered orally BID continuously starting from Cycle 1 Day 1 onwards.
    Other names:
    • Tukysa™
Experimental
Arm J: Trastuzumab Emtansine + Atezolizumab
Participants in this treatment arm must have positive tumor biomarker results for ERBB2 mutation or amplification and TMB high or MSI high/dMMR.
  • Drug: Atezolizumab
    Atezolizumab will be administered by intravenous (IV) infusion at a fixed dose of 1200 mg for participants on Day 1 of each 21-day cycle until unacceptable toxicity or progressive disease (or loss of clinical benefit).
    Other names:
    • Tecentriq®
    • RG7446
    • RO5541267
  • Drug: Trastuzumab Emtansine
    Trastuzumab emtansine will be administered at 3.6 mg per kilogram (kg) of body weight by IV infusion every 21 days (unless dose reduction and/or dose delays are required) until disease progression or unacceptable toxicity.
    Other names:
    • Kadcyla®
    • RG3502
    • RO5304020
Experimental
Arm K: Ipatasertib + Atezolizumab
Participants in this treatment arm must have a positive tumor biomarker result for PI3KCA activating mutation.
  • Drug: Ipatasertib
    Ipatasertib will be self-administered by participants orally at home (except on clinic days), at the same time each day, on a starting dose of 400 mg QD until disease progression, intolerable toxicity, or consent withdrawal.
    Other names:
    • GDC-0068
    • RG7440
    • RO5532961
  • Drug: Atezolizumab
    Atezolizumab will be administered by intravenous (IV) infusion at a fixed dose of 1200 mg for participants on Day 1 of each 21-day cycle until unacceptable toxicity or progressive disease (or loss of clinical benefit).
    Other names:
    • Tecentriq®
    • RG7446
    • RO5541267
Experimental
Arm L: Ipatasertib + Atezolizumab
Participants in this treatment arm must have a positive tumor biomarker result for either AKT1/2/3 activating mutation or PTEN loss/loss of function.
  • Drug: Ipatasertib
    Ipatasertib will be self-administered by participants orally at home (except on clinic days), at the same time each day, on a starting dose of 400 mg QD until disease progression, intolerable toxicity, or consent withdrawal.
    Other names:
    • GDC-0068
    • RG7440
    • RO5532961
  • Drug: Atezolizumab
    Atezolizumab will be administered by intravenous (IV) infusion at a fixed dose of 1200 mg for participants on Day 1 of each 21-day cycle until unacceptable toxicity or progressive disease (or loss of clinical benefit).
    Other names:
    • Tecentriq®
    • RG7446
    • RO5541267
Experimental
Arm M: Ipatasertib + Paclitaxel
Participants in this treatment arm must have a positive tumor biomarker results for PI3KCA activating mutations and either AKT1/2/3 activating mutation or PTEN loss/loss of function.
  • Drug: Ipatasertib
    Ipatasertib will be self-administered by participants orally at home (except on clinic days), at the same time each day, on a starting dose of 400 mg QD until disease progression, intolerable toxicity, or consent withdrawal.
    Other names:
    • GDC-0068
    • RG7440
    • RO5532961
  • Drug: Paclitaxel
    The dose of paclitaxel is 80 mg/m2 administered by IV infusion on Days 1, 8, and 15 of each 28-day cycle. The paclitaxel infusion will be delivered over at least 60 minutes for each dose per institutional guidelines and administered after the oral dose of ipatasertib.
Experimental
Arm N: Atezolizumab + Tiragolumab
Participants in this treatment arm must have a positive tumor biomarker result for either TMB high or MSI high/dMMR.
  • Drug: Atezolizumab
    Atezolizumab will be administered by intravenous (IV) infusion at a fixed dose of 1200 mg for participants on Day 1 of each 21-day cycle until unacceptable toxicity or progressive disease (or loss of clinical benefit).
    Other names:
    • Tecentriq®
    • RG7446
    • RO5541267
  • Drug: Tiragolumab
    Following the administration of atezolizumab and an observation period, participants will receive 600 mg tiragolumab at a fixed dose administered by IV infusion on Day 1 of each 21-day cycle.
    Other names:
    • RG6058
    • RO7092284
    • MTIG7192A
Experimental
Arm O: Pralsetinib
Participants in this treatment arm must have a positive tumor biomarker result for RET fusion.
  • Drug: Pralsetinib
    Pralsetinib will be self-administered by participants orally at home (except on clinic days), at the same time each day, on a starting dose of 400 mg/day (four 100-mg capsules per day) once a day (QD) until disease progression, intolerable toxicity, or consent withdrawal.
    Other names:
    • GAVRETO™
    • RG6396
    • RO7499790

Recruiting Locations

University of Alabama at Birmingham: The Kirklin Clinic
Birmingham, Alabama 35233

More Details

Status
Recruiting
Sponsor
Genentech, Inc.

Study Contact

Reference Study ID Number: ML42439 https://forpatients.roche.com/
888-662-6728 (U.S. Only)
global-roche-genentech-trials@gene.com

Notice

Study information shown on this site is derived from ClinicalTrials.gov (a public registry operated by the National Institutes of Health). The listing of studies provided is not certain to be all studies for which you might be eligible. Furthermore, study eligibility requirements can be difficult to understand and may change over time, so it is wise to speak with your medical care provider and individual research study teams when making decisions related to participation.